Tebentafusp demonstrates superior overall survival (OS) compared to investigator’s choice in Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma

Trial of tebentafusp met pre-defined boundaries for statistical significance of primary endpoint of OS in first pre-planned interim analysis (HR, intent-to-treat population, 0.51, 95% CI: 0.36, 0.71, p<0.0001) over investigator’s choice (pembrolizumab, ipilimumab or dacarbazine).

SPS commentary:

Final results from the Phase 3 trial including 378 patients are expected to be presented at an upcoming scientific conference. Tebentafusp is a first-in-class bi-specific T cell redirector. It binds to a melanocyte-associated target peptide of gp100 presented on the surface of melanoma cells by Human Leukocyte Antigen molecules; once bound it redirects CD-3 positive T cells to kill cancer cells.

Biospace Inc.